Esmolol

Generic Name: Esmolol

Brand Names: Brevibloc

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₅NO_₄

CAS Number: 81147-92-4

Unique Ingredient Identifier: MDY902UXSR

Background: Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decrea...

Indication: For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

Associated Conditions: Hypertension, Tachycardia, Abnormal ventricular rate, Heart rate abnormal

Associated Therapies: -

Clinical Trials

Esmolol for Treatment of Perioperative Tachycardia

Phase 3

Terminated

Conditions: High-risk, Non-cardiovascular Surgeries

Interventions: Drug: Esmolol

First Posted Date: 2010-09-24

Last Posted Date: 2014-12-12

Lead Sponsor: Duke University

Target Recruit Count: 76

Registration Number: NCT01208402

Locations: 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Esmolol Infusion During Laminectomy: Effect on Quality of Recovery

Phase 4

Terminated

Conditions: Laminectomy

Interventions: Drug: Saline
Drug: Esmolol

First Posted Date: 2010-08-11

Last Posted Date: 2016-11-02

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 33

Registration Number: NCT01179113

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

Phase 4

Terminated

Conditions: Pain
Vomiting
Constipation
Nausea

Interventions: Drug: Lidocaine + Esmolol (Combo)
Drug: Lidocaine
Drug: Esmolol

First Posted Date: 2010-05-03

Last Posted Date: 2016-11-03

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 32

Registration Number: NCT01114997

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

Phase 4

Completed

Conditions: Laparoscopic Surgery

Interventions: Drug: Labetalol
Drug: Fentanyl
Drug: Esmolol

First Posted Date: 2010-05-03

Last Posted Date: 2020-02-20

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 75

Registration Number: NCT01114971

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Esmolol in Cardiac Surgery

Phase 4

Completed

Conditions: Cardiac Surgery

Interventions: Drug: Placebo
Drug: Esmolol

First Posted Date: 2009-08-14

Last Posted Date: 2018-10-10

Lead Sponsor: Università Vita-Salute San Raffaele

Target Recruit Count: 200

Registration Number: NCT00959569

Locations: 🇮🇹
Vita-Salute University, Milano, Italy

Influence of Esmolol on a Closed-Loop Anesthesia System

Phase 3

Terminated

Conditions: Anesthesia

Interventions: Drug: NaCl 9/00
Drug: Esmolol

First Posted Date: 2009-06-17

Last Posted Date: 2016-09-23

Lead Sponsor: Hopital Foch

Target Recruit Count: 15

Registration Number: NCT00922467

Locations: 🇫🇷
Hôpital Foch, Suresnes, France

A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement

Not Applicable

Completed

Conditions: Myocardial Ischemia

Interventions: Drug: P-Group
Drug: Metoprolol
Drug: Esmolol

First Posted Date: 2008-09-22

Last Posted Date: 2017-07-31

Lead Sponsor: University of Oklahoma

Target Recruit Count: 60

Registration Number: NCT00756236

Locations: 🇺🇸
Univeristy of Oklahoma Health Sciences Center Dept. Anesthesiology, Oklahoma City, Oklahoma, United States

Safety Study of Tecadenoson to Treat Atrial Fibrillation

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Tecadenoson
Drug: Esmolol

First Posted Date: 2008-07-11

Last Posted Date: 2014-03-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 21

Registration Number: NCT00713401

Locations: 🇺🇸
CV Therapeutics, Inc., Palo Alto, California, United States

Use of Beta Blockers in Elderly Trauma Patients

Phase 2

Conditions: Multiple Trauma
Cardiovascular Diseases
Aged

First Posted Date: 2006-03-14

Last Posted Date: 2007-05-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 148

Registration Number: NCT00302692

Locations: 🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Not Applicable

Completed

Conditions: CVA (Cerebrovascular Accident)
Cerebral Hemorrhage
Intracranial Hemorrhages

First Posted Date: 2005-09-26

Last Posted Date: 2008-06-26

Lead Sponsor: The George Institute

Target Recruit Count: 404

Registration Number: NCT00226096

Locations: 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy